Market Insight: Adc Therapeutics SA (ADCT)’s Notable Drop, Closing at 2.14

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Adc Therapeutics SA (NYSE: ADCT) closed at $2.14 down -10.46% from its previous closing price of $2.39. In other words, the price has decreased by -$10.46 from its previous closing price. On the day, 0.5 million shares were traded. ADCT stock price reached its highest trading level at $2.4 during the session, while it also had its lowest trading level at $2.13.

Ratios:

For a deeper understanding of Adc Therapeutics SA’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.68 and its Current Ratio is at 4.92.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Overweight rating and assigned the stock a target price of $6.

On March 28, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $11.Guggenheim initiated its Buy rating on March 28, 2024, with a $11 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 01 ’24 when Redmile Group, LLC bought 400,000 shares for $2.81 per share. The transaction valued at 1,124,000 led to the insider holds 15,669,217 shares of the business.

Redmile Group, LLC bought 400,000 shares of ADCT for $1,124,000 on Jul 01 ’24. The 10% Owner now owns 12,995,040 shares after completing the transaction at $2.81 per share. On Jun 17 ’24, another insider, Azelby Robert, who serves as the Director of the company, sold 6,995 shares for $2.89 each. As a result, the insider received 20,216 and left with 53,005 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADCT now has a Market Capitalization of 206915760 and an Enterprise Value of 387039776. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.64. Its current Enterprise Value per Revenue stands at 5.473 whereas that against EBITDA is -2.828.

Stock Price History:

Over the past 52 weeks, ADCT has reached a high of $6.04, while it has fallen to a 52-week low of $0.57. The 50-Day Moving Average of the stock is -28.79%, while the 200-Day Moving Average is calculated to be -41.23%.

Shares Statistics:

For the past three months, ADCT has traded an average of 368.46K shares per day and 493090 over the past ten days. A total of 82.29M shares are outstanding, with a floating share count of 77.83M. Insiders hold about 19.50% of the company’s shares, while institutions hold 55.29% stake in the company. Shares short for ADCT as of 1730332800 were 3167562 with a Short Ratio of 8.60, compared to 1727654400 on 3557234. Therefore, it implies a Short% of Shares Outstanding of 3167562 and a Short% of Float of 4.68.

Most Popular